Post-market clinical follow-up study of the MobileLink Hip cup system

  • Research type

    Research Study

  • Full title

    Clinical and functional outcome of the MobileLink acetabular cup system in the short-, mid- and long-term follow-up

  • IRAS ID

    293126

  • Contact name

    Muhammad Adeel Akhtar

  • Contact email

    adeel.akhtar@nhs.scot

  • Sponsor organisation

    Waldemar Link GmbH & Co. KG

  • Clinicaltrials.gov Identifier

    NCT04688593

  • Duration of Study in the UK

    12 years, 3 months, 1 days

  • Research summary

    The newly developed MobileLink acetabular cup system is used in total hip arthroplasty and intended for a long-term replacement of a diseased and / or defective acetabulum. According to the current knowledge the MobileLink acetabular cup system is state of the art and its benefit / risk profile is acceptable. However, currently no clinical data is available for the MobileLink acetabular cup system itself. With this prospective, multi-center, open-label case series study its safety and performance under real world conditions shall be confirmed to identify previously unknown and to monitor already identified side effects in the short-, mid- and long-term follow-up. To measure the performance, the 3 month, 1, 3, 5, 7 and 10-year survival rates of the complete MobileLink acetabular cup system and the different components are used as endpoints. In addition, the patient reported outcome, occurred complications and re-operations of the hip joint, the radiological outcome and the handling with the surgical instruments is requested. All adult patients who undergo a total hip arthroplasty (THA) with usage of a MobileLink acetabular cup system shall be potentially included. The decision to implant a MobileLink acetabular cup system is made by the treating surgeon independently from the study. Data on the preoperative visit, the surgery itself and the discharge is collected. Additionally, the patients need to visit the study site at the mentioned follow-up time points, answer a short interview and one questionnaires. In total 520 patients (at four study sites in Germany and Scotland) shall be recruited within a maximum recruiting period of two years.

  • REC name

    East Midlands - Nottingham 1 Research Ethics Committee

  • REC reference

    21/EM/0122

  • Date of REC Opinion

    21 May 2021

  • REC opinion

    Further Information Favourable Opinion